Astatine-211-Labeled Therapy Targeting Amino Acid Transporters: Overcoming Drug Resistance in Non-Small Cell Lung Cancer
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms262110736 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Sifan Feng und 4 weiteren Autor:innen. Beteiligte Einrichtung: Radiation Biological Chemistry, Department of Chemistry, Graduate School of Science, The University of Osaka, Osaka 560-0043, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Drug Resistance, Neoplasm, Astatine. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 238 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: JSPS KAKENHI.
Abstract (Originalsprache)
Non-small cell lung cancer (NSCLC) remains a leading cause of cancer mortality, with therapeutic resistance posing the primary barrier to durable outcomes. Beyond genetic and epigenetic alterations, amino acid transporter-driven metabolic reprogramming—mediated by LAT1 (SLC7A5), ASCT2 (SLC1A5), and xCT (SLC7A11)—supports tumor proliferation, redox homeostasis, and immune escape. Their preferential expression in NSCLC highlights their potential as therapeutic targets and predictive biomarkers. In parallel, α-particle therapy has gained attention for its capacity to eradicate resistant clones through densely clustered, irreparable DNA double-strand breaks. Astatine-211 (211At) combines a clinically relevant half-life, high linear energy transfer, and predictable decay scheme, positioning it as a unique candidate among α-emitters. Preclinical studies of 211At-labeled transporter ligands, particularly LAT1-targeted conjugates, demonstrate potent tumor suppression and synergy with targeted therapy, chemotherapy, radiotherapy, immunotherapy, and ferroptosis inducers. Advances in radiochemistry, delivery systems (antibodies, peptides, and nanocarriers), and PET tracers such as [18F]FAMT and [18F]FSPG collectively support a theranostic framework for patient stratification and adaptive dosing. By linking transporter biology with α-particle delivery, 211At-based theranostics offer a mechanistically orthogonal strategy to overcome resistance and heterogeneity in NSCLC. Successful translation will depend on precise dosimetry, scaffold stabilization, and biomarker-guided trial design, enabling progression toward first-in-human studies and future integration into multimodal NSCLC therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Radiation Biological Chemistry, Department of Chemistry, Graduate School of Science, The University of Osaka, Osaka 560-0043, Japan.
- Institute for Radiation Sciences, The University of Osaka, Osaka 565-0871, Japan.
- Core for Medicine and Science Collaborative Research and Education, Forefront Research Center, Graduate School of Science, The University of Osaka, Osaka 560-0043, Japan.
ORCID-Profile: Yoshifumi Shirakami, Kazuko Kaneda-Nakashima
Förderung
- JSPS KAKENHI
Zitieren
APA
Feng, S., Hisada, K., Yorifuji, H., Shirakami, Y., & Kaneda-Nakashima, K. (2025). Astatine-211-Labeled Therapy Targeting Amino Acid Transporters: Overcoming Drug Resistance in Non-Small Cell Lung Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262110736
Vancouver
Feng S, Hisada K, Yorifuji H, Shirakami Y, Kaneda-Nakashima K. Astatine-211-Labeled Therapy Targeting Amino Acid Transporters: Overcoming Drug Resistance in Non-Small Cell Lung Cancer. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262110736
BibTeX
@article{Feng2025,
author = {Feng, Sifan and Hisada, Kentaro and Yorifuji, Haruna and Shirakami, Yoshifumi and Kaneda-Nakashima, Kazuko},
title = {Astatine-211-Labeled Therapy Targeting Amino Acid Transporters: Overcoming Drug Resistance in Non-Small Cell Lung Cancer},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms262110736}
}
EUVIMED